Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIM 23A760 in Acromegaly
NCT00994214Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Oct 2009
- Primary completion
- Feb 2011
- Modality
- Peptides, Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of onzigolide in acromegaly (4 arms), sponsored by Ipsen. Primary endpoint: Percentage of Subjects With Mean GH <=2.5 ng/mL and Normalised IGF-1 at 6 months. Started Oct 2009; status: terminated.
02
Drugs
onzigolide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00994214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00994214.